Populations deemed to most likely benefit from CCL14 testing were patients with AKI Stage 2 or 3 following cardiac surgery (53/64 points), and AKI stage 2 or 3 patients with heart failure (53/64 points), followed by patients with sepsis (52/64), or post-surgery (50/64 points), and any ICU patients with AKI stage 3 (50/64 points) (Table 2). Here, CCL14 is linked to heart failure.